Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Mazitschek

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Scientific Reports|April 20, 2024
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementiaZachary C Rosenthal, Daniel M Fass, N Connor Payne, et al.
Neuropharmacology|July 10, 2012
Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticityDaniel M Fass, Surya A Reis, Balaram Ghosh, et al.
Nature Communications|August 25, 2022
Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistanceMark A Tye, N Connor Payne, Catrine Johansson, et al.
Blood|January 21, 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaLoredana Santo, Teru Hideshima, Andrew L Kung, et al.
Nature Neuroscience|June 8, 2023
Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injuryKerri D Pryce, Randal A Serafini, Aarthi Ramakrishnan, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
Nature Neuroscience|January 22, 2024
Author Correction: Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injuryKerri D Pryce, Randal A Serafini, Aarthi Ramakrishnan, et al.
Analytical Chemistry|November 7, 2025
Spatial Profiling of Elements through Matrix-Assisted Laser Desorption Ionization Mass Spectrometry ImagingSylwia A Stopka, Clément Bodineau, Gerard Baquer, et al.
Advanced Materials (Deerfield Beach, Fla.)|January 19, 2024
Inhibiting the Keap1/Nrf2 Protein-Protein Interaction with Protein-Like PolymersKendal P Carrow, Haylee L Hamilton, Madeline P Hopps, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseJames E Bradner, Raymond Mak, Shyam K Tanguturi, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Scientific Reports|April 20, 2024
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementiaZachary C Rosenthal, Daniel M Fass, N Connor Payne, et al.
Neuropharmacology|July 10, 2012
Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticityDaniel M Fass, Surya A Reis, Balaram Ghosh, et al.
Nature Communications|August 25, 2022
Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistanceMark A Tye, N Connor Payne, Catrine Johansson, et al.
Blood|January 21, 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaLoredana Santo, Teru Hideshima, Andrew L Kung, et al.
Nature Neuroscience|June 8, 2023
Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injuryKerri D Pryce, Randal A Serafini, Aarthi Ramakrishnan, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
Nature Neuroscience|January 22, 2024
Author Correction: Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injuryKerri D Pryce, Randal A Serafini, Aarthi Ramakrishnan, et al.
Analytical Chemistry|November 7, 2025
Spatial Profiling of Elements through Matrix-Assisted Laser Desorption Ionization Mass Spectrometry ImagingSylwia A Stopka, Clément Bodineau, Gerard Baquer, et al.
Advanced Materials (Deerfield Beach, Fla.)|January 19, 2024
Inhibiting the Keap1/Nrf2 Protein-Protein Interaction with Protein-Like PolymersKendal P Carrow, Haylee L Hamilton, Madeline P Hopps, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseJames E Bradner, Raymond Mak, Shyam K Tanguturi, et al.
Pageof 14